Patents by Inventor Stefan Wawersik

Stefan Wawersik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TGFB INHIBITORS AND USE THEREOF
    Publication number: 20230057012
    Abstract: Disclosed herein are novel inhibitors of TGF?1 activation with durable inhibitory effects. Methods directed to the selection of a suitable TGF? inhibitor for various disease conditions and patient populations are also provided.
    Type: Application
    Filed: January 11, 2021
    Publication date: February 23, 2023
    Inventors: Stefan Wawersik, Thomas Schurpf, Christopher Chapron, Sandeep Kumar, Adam Fogel
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20220363741
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 17, 2022
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, JR.
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 11365245
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: June 21, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • METHODS FOR TREATING METABOLIC DISEASES BY INHIBITING MYOSTATIN ACTIVATION
    Publication number: 20220106390
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
    Type: Application
    Filed: September 22, 2021
    Publication date: April 7, 2022
    Inventors: Adriana DONOVAN, Michelle STRAUB, Stefan WAWERSIK, Yung CHYUNG, Micah WEBSTER
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20220064276
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 3, 2022
    Inventors: Thomas SCHURPF, Justin W. JACKSON, George CORICOR, Abhishek DATTA, Stefan WAWERSIK, Christopher LITTLEFIELD, Adam FOGEL, Caitlin STEIN, Julia McCREARY, Matthew SALOTTO, Frederick STREICH, JR.
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20220064275
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: August 19, 2021
    Publication date: March 3, 2022
    Inventors: Abhishek DATTA, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. DAGBAY, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
  • LTBP complex-specific inhibitors of TGF? and uses thereof
    Patent number: 11214614
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: January 4, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich, Jr.
  • TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210340238
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: November 4, 2021
    Inventors: Abhishek Datta, Thomas Schurpf, Allan Capili, Stefan Wawersik, Christopher Chapron, Christopher Littlefield, Gregory J. Carven, Kevin B. Dagbay, Susan Lin, Justin W. Jackson, Caitlin Stein
  • METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES
    Publication number: 20210332117
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Application
    Filed: October 29, 2020
    Publication date: October 28, 2021
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • Compositions and methods for making and using anti-myostatin antibodies
    Patent number: 11155611
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 26, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Stefan Wawersik, Yung Chyung, Micah Webster
  • Isoform-selective TGF?1 inhibitors and use thereof
    Patent number: 11130803
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: September 28, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
  • HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210122814
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: April 29, 2021
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
    Publication number: 20210047396
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: August 19, 2020
    Publication date: February 18, 2021
    Inventors: Thomas Schurpf, Justin W. Jackson, George Coricor, Abhishek Datta, Stefan Wawersik, Christopher Littlefield, Adam Fogel, Caitlin Stein, Julia McCreary, Matthew Salotto, Frederick Streich
  • Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
    Patent number: 10882904
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: January 5, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • LRRC33 INHIBITORS AND USE THEREOF
    Publication number: 20200181251
    Abstract: Disclosed herein are LRRC33 inhibiting agents and related methods and uses thereof. More specifically, therapeutic agents for inhibiting LRRC33 effects in vivo are provided. Such agents are useful for the treatment of various disorders involving cells expressing LRRC33 or LRRC33-containing complexes on the surface of cells.
    Type: Application
    Filed: May 9, 2018
    Publication date: June 11, 2020
    Inventors: Alan Buckler, Gregory J. Carven, Stefan Wawersik, Thomas Schurpf, Constance Martin, Abhishek Datta, Mark Allen Farmer
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20200079840
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: March 12, 2020
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson
  • METHODS FOR TREATING METABOLIC DISEASES BY INHIBITING MYOSTATIN ACTIVATION
    Publication number: 20190345239
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 14, 2019
    Inventors: Adriana DONOVAN, Michelle STRAUB, Stefan WAWERSIK, Yung CHYUNG, Micah WEBSTER
  • METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES
    Publication number: 20190218283
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Application
    Filed: March 21, 2019
    Publication date: July 18, 2019
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
    Patent number: 10287345
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 14, 2019
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • ANTI-PRO/LATENT MYOSTATIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170198032
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Application
    Filed: January 6, 2017
    Publication date: July 13, 2017
    Applicant: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik